Custom Search

Risperidone News

SCOLR Announces Completion of 12 hour CDT-Pseudoephedrine ANDA Registration Batches, New Drug Development Targets

SCOLR Pharma, Inc. (Amex: DDD) announced today that its contract manufacturing partner, Cardinal Healthcare, has produced batches of SCOLR's 12 hour CDT-based pseudoephedrine tablets needed for the completion of its Abbreviated...

FDA Grants Pediatric Exclusivity for Risperdal

The U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for RISPERDAL(R) (risperidone), based on studies conducted in bipolar 1 disorder and schizophrenia. The patent is set to expire in December 2007,...

Link Found Between Antipsychotic Drugs and Weight Gain

In what may be a major breakthrough for the research and development of antipsychotic drugs, brain scientists at Johns Hopkins University believe they have discovered a major cause of the weight gain suffered by many patients...

Evidence Lacking to Support Many Off-Label Uses of Atypical Antipsychotics

Some newer antipsychotic medications approved to treat schizophrenia and bipolar disorder are being prescribed to millions of Americans for depression, dementia, and other psychiatric disorders without strong evidence that such...

Invega (paliperidone), Son of Risperdal (risperidone), Wins FDA Okay for Schizophrenia

The FDA today approved Invega (paliperidone) for treatment of acute schizophrenia.

Displaying results 16 to 20 out of 37

< Previous








Next >

Use of this site is subject to the following terms of use